Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls.

Cedric Menard 1, 2 Luciano Pacelli 3 Giulio Bassi 3 Joelle Dulong 1 Francesco Bifari 3 Isabelle Bezier 1, 2 Jasmina Zanoncello 3 Mario Ricciardi 3 Maelle Latour 2 Philippe Bourin 4 Hubert Schrezenmeier 5 Luc Sensebé 4 Karin Tarte 1, * Mauro Krampera 3
* Auteur correspondant
1 MiCa - Microenvironnement et cancer
2 EFS Bretagne - Etablissement français du sang [Rennes]
3 Stem Cell Research Laboratory
4 STROMALab
5 Institut für Klinische Transfusionmedizin und Immungenetik
Abstract : Clinical-grade mesenchymal stromal cells (MSCs) are usually expanded from bone marrow (BMMSCs) or adipose tissue (ADSCs) using processes mainly differing in the use of fetal calf serum (FCS) or human platelet lysate (PL). We aimed to compare immune modulatory properties of clinical-grade MSCs using a combination of fully standardized in vitro assays. BMMSCs expanded with FCS (BMMSC-FCS) or PL (BMMSC-PL), and ADSC-PL were analyzed in quantitative phenotypic and functional experiments, including their capacity to inhibit the proliferation of T, B, and NK cells. The molecular mechanisms supporting T-cell inhibition were investigated. These parameters were also evaluated after pre-stimulation of MSCs with inflammatory cytokines. BMMSC-FCS, BMMSC-PL, and ADSC-PL displayed significant differences in expression of immunosuppressive and adhesion molecules. Standardized functional assays revealed that resting MSCs inhibited proliferation of T and NK cells, but not B cells. ADSC-PL were the most potent in inhibiting T-cell growth, a property ascribed to interferon-γ-dependent indoleamine 2,3-dioxygenase activity. MSCs did not stimulate allogeneic T cell proliferation but were efficiently lysed by activated NK cells. The systematic use of quantitative and reproducible validation techniques highlights differences in immunological properties of MSCs produced using various clinical-grade processes. ADSC-PL emerge as a promising candidate for future clinical trials.
Type de document :
Article dans une revue
Stem Cells and Development, Mary Ann Liebert, 2013, 22 (12), pp.1789-801. 〈10.1089/scd.2012.0594〉
Liste complète des métadonnées

Littérature citée [51 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-00799812
Contributeur : Cédric Ménard <>
Soumis le : mardi 25 février 2014 - 07:00:05
Dernière modification le : mercredi 10 octobre 2018 - 20:30:03
Document(s) archivé(s) le : dimanche 25 mai 2014 - 10:35:48

Fichiers

inserm-00799812_edited.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

U917 | BIOSIT | UNIV-TLSE3 | UR1-UFR-SVE | MICMAC | UNIV-RENNES

Citation

Cedric Menard, Luciano Pacelli, Giulio Bassi, Joelle Dulong, Francesco Bifari, et al.. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls.. Stem Cells and Development, Mary Ann Liebert, 2013, 22 (12), pp.1789-801. 〈10.1089/scd.2012.0594〉. 〈inserm-00799812〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

461

Téléchargements de fichiers

1023

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD